Acturadar.comFrance in real time

English translation in progress — this text is still shown in French.

Anti-obesity drugs in France: controls, reimbursement and off-label uses

Ongoing22 events · of the 28 Oct au 14 Nov · latest fact at 15h40

View entire story

Fact 21 of 22 in the story · Saturday 14 November, 15h00

Les médicaments anti-obésité explorent de nouveaux usages thérapeutiques

Les traitements anti-obésité de type GLP-1 font l'objet de recherches sur de nouvelles indications, notamment l'AVC et les addictions, alors que leur coût reste élevé hors remboursement.

In brief

Health event (severity: low) nationwide, first detected on 14 November 2026 at 15:00. Reported by 1 source (1 article), last updated on 14 November 2026 at 15:00. Part of the story “Anti-obesity drugs in France: controls, reimbursement and off-label uses”.

·
Category
Health
Severity
Low
Place

National

Detected
14 Nov, 15h00
Updated
14 Nov, 15h00
Reference
no.20250
01

What changed in the story at that point

02

Who is covering it, and from what angle

Method
1Right

1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 0, right 1

Story angles

This event does not yet have its own comparison: here is the story's Anti-obesity drugs in France: controls, reimbursement and off-label uses.

The three sides cover the same issue (the arrival of oral Wegovy, French enthusiasm, risks and trafficking), but differ in angle: the left prioritizes testimonies and individual health risks, the center extensively covers the Ifop poll and practical alerts, the right highlights the market explosion, side effects and economic and regulatory aspects.

Left

Highlights personal testimonies (a patient who lost weight without medication, a formerly obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.

Centre

Extensively covers the Ifop poll (one in five French people tempted, even without being obese), health professionals' alerts on injections and harmful substances, influencers diverting medications, and customs controls against trafficking.

Right

Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.

Common points

  • =Wegovy is now available in tablet form in France since early November
  • =Around one in five French people consider using GLP-1s to lose weight according to the Ifop survey
  • =Health professionals and authorities warn about risks and side effects
  • =Off-label uses and illegal purchases or parallel markets are reported

Divergences

  • ≠The left insists on weight-loss testimonies without medication and individual warnings, an angle little present in the center and on the right
  • ≠The right highlights the market explosion, side effects and economic impact, more than the left
  • ≠The center develops influencer cases and customs trafficking as a main angle, less central on the left and right

Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44

03

Lire les sources · 1 article, 1 source

Publication order
  1. 15h00
    Les ÉchosCentre-rightAnalysisvia Google Actualités France14 Nov
    AVC, Addiction… : les nouveaux horizons thérapeutiques des médicaments anti-obésité - Les Echos

    AVC, Addiction… : les nouveaux horizons thérapeutiques des médicaments anti-obésité Les Echos QUIZ. Wegovy, Mounjaro… Les médicaments anti-obésité font parler, mais savez-vous vraiment comment ils fonctionnent Ouest-France Obésité : hors critères de la Sécu, Wegovy coûte plus de 2 300 € par an, et seule une bonne mutuelle en rembourse un peu JeChange TÉMOIGNAGE. "Je ne voulais ni opération ni médicament" : face à l'arrivée du Wegovy, cette Gersoise raconte comment elle a perdu 30 kilos ladepeche.fr

04

Further reading